Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange - Seite 2

Idorsia will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases.

Idorsia's drug discovery will focus on novel molecular target families, implementing appropriate state-of-the-art technologies. In particular, the target families will include G-protein coupled receptors (GPCRs), ion channels and certain enzymes.

Status		Compound		Mechanism of Action		Target Indication
Phase 2		Aprocitentan (ACT-132577)		Endothelin receptor antagonist		Resistant hypertension
		ACT-541468		Dual orexin receptor antagonist		Chronic insomnia
		Clazosentan		Endothelin receptor antagonist		Vasospasm associated with aneurysmal subarachnoid hemorrhage
		Cenerimod		S1P1 receptor modulator		Systemic lupus erythematosus
Phase 1b		Lucerastat		Glucosylceramide synthase inhibitor		Fabry disease
Phase 1		ACT-246475		P2Y12 receptor antagonist		Acute coronary syndrome
		ACT-774312		CRTH2 receptor antagonist		Asthma and allergy disorders
		ACT-539313		Selective orexin 1 receptor antagonist		Anxiety
		ACT-709478		T-type calcium channel blocker		Epilepsy

Corporate Governance